Small cell lung cancer enters the era of precision medicine
Authors:
- 1 March 2021
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 39 (3) , 297-299
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Bayer
- GlaxoSmithKline
- Merck
- British Microcirculation & Vascular Biology Society
- Amgen
- CRUK Lung Cancer Centre of Excellence (A20465)
- Boehringer Ingelheim
- Astex Pharmaceuticals
- Cancer Research UK
- Novartis
- Roche
This publication has 8 references indexed in Scilit:
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCancer Cell, 2021
- The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief ReportJournal of Thoracic Oncology, 2020
- SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic CharacterizationJournal of Thoracic Oncology, 2020
- MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine FateCancer Cell, 2020
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model dataNature Reviews Cancer, 2019
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancerNature, 2017
- A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung CancerCancer Cell, 2011